1167 — Jacobio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$3.91bn
- HK$2.13bn
- CNY53.53m
Brief: Jacobio Pharmaceuticals Gets China CDE Clearance
China's Jacobio hits 9-week peak on submission of new drug application
Brief: Jacobio Pharmaceuticals Says Submission Of New Drug Application
Brief: Jacobio Pharmaceuticals Says Loss For Year Rmb359.1 Million
Brief: Jacobio Pharmaceuticals Says Noted Recent Unusual Fluctuation In Price Of Shares
Brief: Jacobio Pharmaceuticals Received U.S. FDA Investigational New Drug Clearance
Brief: Jacobio Pharmaceuticals Says Revenue Of Rmb40.3 Million For Six Months
Brief: Jacobio Pharma Announces Breakthrough Therapy Designation From China CDE For KRAS G12C Inhibitor Glecirasib For The Treatment Of Pancreatic Cancer
Brief: Jacobio Pharmaceuticals Says Kras G12c Inhibitor Jab-21822 (Glecirasib) Granted Breakthrough Therapy Designation
Brief: Jacobio Pharmaceuticals Intends To Conduct On-Market Share Repurchase
Brief: Jacobio Pharmaceuticals Enters Capital Increase Agreement
Brief: Jacobio Pharmaceuticals Says Abbvie Sent Termination Notice Of Deal For Development Of Shp2 Inhibitors
Brief: Jacobio Gets CDE Approval For Glecirasib's Pancreatic Cancer Pivotal Study In China
Brief: Jacobio Pharmaceuticals Announces IND Approval- For Parp7 Inhibitor Jab-26766 By China's NMPA
Brief: Jacobio Pharmaceuticals Says Loss For Year Was RMB371.9 Million
Brief: Jacobio Pharmaceuticals Says Received IND Approval For GUE Inhibitor JAB-24114
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Six Hong Kong-listed firms say their deposits at SVB are immaterial
China's Jacobio hits 9-mth high on share sale for clinical trials